Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

March 31, 2016

Conditions
Ovarian Cancer
Interventions
DRUG

vargatef

"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."

DRUG

placebo

"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."

Trial Locations (36)

Unknown

Centre Paul Papin, Angers

Institut Ste Catherine, Avignon

Clinique Tivoli, Bordeaux

Institut Bergonié, Bordeaux

Polyclinique Bordeaux Nord, Bordeaux

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Hospitalier Alpes Leman, Contamine-sur-Arve

Centre Hospitalier Intercommunal de Créteil, Créteil

Centre Hospitalier de Dax, Dax

Centre Georges François Leclerc, Dijon

Centre Hospitalier Régional Universitaire de Lille - Hôpital Huriez, Lille

Centre Oscar Lambret, Lille

Centre Hospitalier Universitaire Dupuytren, Limoges

Centre Léon bérard, Lyon

ICM Val d'Aurelle, Montpellier

Centre Catherine de Sienne, Nantes

Hôpital Privé du Confluent S.A.S., Nantes

Centre Antoine Lacassagne, Nice

Centre Hospitalier Régional, Orléans

Hôpital Cochin, Paris

Hôpital Européen Georges Pompidou, Paris

Hôpital Tenon, Paris

Institut Mutualiste Montsouris-Jourdan, Paris

Centre Hospitalier Lyon-sud, Pierre-Bénite

Milétrie - Centre Hospitalier Universitaire de Poitiers, Poitiers

Institut Jean Godinot, Reims

Centre Henri Becquerel, Rouen

Clinique Armoricaine de Radiologie, Saint-Brieuc

Hôpital René Huguenin, Saint-Cloud

ICO René Gauducheau, Saint-Herblain

Hôpital Civil, Strasbourg

Hôpitaux Du Leman, Thonon-les-Bains

Centre Claudius Régaud, Toulouse

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

Gustave Roussy, Villejuif

All Listed Sponsors
lead

ARCAGY/ GINECO GROUP

OTHER

NCT01583322 - Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter